Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach

NCT06068257 is registered in ClinicalTrials.gov with University of Central Florida as lead sponsor.

NCT NCT06068257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach
Lead sponsor
University of Central Florida
Phase
Observational
Overall status
Completed
Start date
June 6, 2023
Completion date
July 1, 2026
Enrollment
119 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, healthy